News
RNXT
1.130
-5.04%
-0.060
RenovoRx’s Growing Commercial Traction and Pipeline Expansion Support Buy Rating; $3 Price Target Unchanged
TipRanks · 3h ago
RenovoRx GAAP EPS of -$0.08 misses by $0.02, revenue of $1.07M beats by $0.01M
Seeking Alpha · 13h ago
RenovoRx backs FY26 revenue view $3.75M-$4.25M, consensus $3.87M
TipRanks · 1d ago
Press Release: RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
Dow Jones · 1d ago
Press Release: RenovoRx Reports Record Third -2-
Dow Jones · 1d ago
Weekly Report: what happened at RNXT last week (1026-1030)?
Weekly Report · 4d ago
Weekly Report: what happened at RNXT last week (1019-1023)?
Weekly Report · 10/26 10:23
Weekly Report: what happened at RNXT last week (1012-1016)?
Weekly Report · 10/19 10:23
Weekly Report: what happened at RNXT last week (1005-1009)?
Weekly Report · 10/12 10:29
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/09 21:05
RenovoRx Enrolls First Patient In UVM-Sponsored Pancreatic Cancer PRISM-TAMP Trial
NASDAQ · 10/08 09:29
RenovoRx enrolls first patient in PRISM-TAMP trial
TipRanks · 10/07 12:45
RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study
Benzinga · 10/07 12:35
Weekly Report: what happened at RNXT last week (0928-1002)?
Weekly Report · 10/05 10:29
RenovoRx announces publication on TAMP platform’s potential
TipRanks · 10/01 12:55
RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center
Benzinga · 10/01 12:39
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
Barchart · 10/01 07:30
Weekly Report: what happened at RNXT last week (0921-0925)?
Weekly Report · 09/28 10:23
Weekly Report: what happened at RNXT last week (0914-0918)?
Weekly Report · 09/21 10:24
Weekly Report: what happened at RNXT last week (0907-0911)?
Weekly Report · 09/14 10:29
More
Webull provides a variety of real-time RNXT stock news. You can receive the latest news about Renovorx Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.